Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

Arthritis Care and Research

Volumn 59, Issue 10, 2008, Pages 1371-1377

  Aletaha, D ^a   Landewe, R ^b   Karonitsch, T ^a   Bathon, J ^c   Boers, M ^d   Bombardier, C ^e   Bombardieri, S ^f   Choi, H ^g   Combe, B ^h   Dougados, M ⁱ   Emery, P ^j   Gomez Reino, J ^k   Keystone, E ^l   Koch, G ^m   Kvien, T K ⁿ   Martin Mola, E ^o   Matucci Cerinic, M ^p   Michaud, K ^q   O'Dell, J ^q   Paulus, H ^r   Pincus, T ^s   Richards, P ^t   Simon, L ^u   Siegel, J ^v   Smolen, J S ^a   Sokka, T ^w   Strand, V ^x   Tugwell, P ^y   Van Der Heijde, D ^z   Van Riel, P ^aa   Vlad, S ^ab   Van Vollenhoven, R ^ac   Ward, M ^ad   Weinblatt, M ^ae   Wells, G ^af   White, B ^ag   Wolfe, F ^ah   Zhang, B ^ab   Zink, A ^ai   Felson, D ^ab   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSTITUTE FOR WORK AND HEALTH   (Canada)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^l UNIVERSITY OF TORONTO   (Canada)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

ⁿ DIAKONHJEMMET HOSPITAL   (Norway)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p UNIVERSITY OF FLORENCE   (Italy)

^q UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s NYU HOSPITAL FOR JOINT DISEASES   (United States)

^t UNIVERSITY OF BRISTOL   (United Kingdom)

^u BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^v CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^w JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^x STANFORD UNIVERSITY   (United States)

^y Institute of Population Health   (Canada)

^z LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^aa RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ab BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ad NATIONAL INSTITUTES OF HEALTH   (United States)

^ae BRIGHAM AND WOMEN S HOSPITAL   (United States)

^af UNIVERSITY OF OTTAWA   (Canada)

^ag MEDIMMUNE   (United States)

^ah NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^ai CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE ACTIVITY; FATIGUE; HEALTH CARE ORGANIZATION; MEDICAL RESEARCH; REMISSION; RHEUMATOID ARTHRITIS; STANDARDIZATION; STATISTICAL ANALYSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 53149147037     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24123     Document Type: Article

References (19)

1. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
2. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
3. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:S86-9.
4. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
6. US Food and Drug Administration. FDA guidance paper. Rockville (MD): Food and Drug Administration; 1999.
7. European Medicines Agency. EMEA points to consider. London: EMEA; 1999.
8. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
9. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854-60.
10. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784-92.
11. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57.
12. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
13. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007;57:193-202.
14. Kirwan JR, Hewlett SE, Heiberg T, Hughes RA, Carr M, Hehir M, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis: progress at OMERACT 7. J Rheumatol 2005;32:2250-6.
15. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007;34:1188-93.
16. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
17. Aletaha D, Landewe RB, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
18. Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, et al. Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:1365-73
19. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.